Avadel Pharmaceuticals plc (AWK)
XSTU 
Summary
AWK Chart
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District Court”) in favor of the U.S. Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure
ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avadel Pharmaceuticals plc Dividends
Avadel Pharmaceuticals plc Earnings
| 6 Aug 2025 (In 1 month) Date | | 0.04 Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 3 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 1 month) Date | | 0.04 Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 3 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Avadel Pharmaceuticals plc (AWK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Avadel Pharmaceuticals plc ever had a stock split?
Avadel Pharmaceuticals plc Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Gregory J. Divis Jr. CEO | XSTU Exchange | US05337M1045 ISIN |
| IE Country | 188 Employees | - Last Dividend | - Last Split | 7 Jun 1996 IPO Date |
Overview
Avadel Pharmaceuticals plc is a biopharmaceutical firm based in the United States, with its headquarters in Dublin, Ireland. Initially founded as Flamel Technologies SA, the company underwent a name change to Avadel Pharmaceuticals plc in January 2017, signaling a new phase in its journey since its incorporation in 2015. The company specializes in developing and delivering pharmaceutical products, focusing on therapies that address unmet medical needs. Avadel Pharmaceuticals plc has carved a niche for itself in the biopharmaceutical industry through its innovative drug development programs and a commitment to improving the lives of patients suffering from various conditions.
Products and Services
- LUMRYZ - This is Avadel Pharmaceuticals plc's lead product candidate, currently in a Phase 3 clinical trial. LUMRYZ is a formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. By targeting these symptoms, LUMRYZ aims to significantly improve the quality of life for individuals affected by narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep.
Contact Information
